{"entity":{"id":"leo-pharma","kind":"company","name":"LEO Pharma","aka":["LEO Pharma A/S"],"tldr":"LEO Pharma is a foundation-owned Danish dermatology company whose cancer-related trials concern actinic keratosis, the precancerous skin lesion that can progress to squamous cell carcinoma.","summary":"LEO Pharma, based in Ballerup near Copenhagen and majority-owned by the LEO Foundation, specialises in medical dermatology. Its registry footprint in cancer comes from actinic keratosis, the sun-damage lesion that can progress to cutaneous squamous cell carcinoma: it marketed ingenol mebutate gel (Picato) for the condition until the product's EU authorisation was withdrawn in 2020 over a possible skin cancer signal. OnCo records it so that those phase 3 trials resolve to a sponsor page.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.leo-pharma.com"},{"label":"ClinicalTrials.gov: trials led by LEO Pharma","url":"https://clinicaltrials.gov/search?lead=LEO%20Pharma"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/LEO_Pharma"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cutaneous-scc"],"sections":["prevention"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Ballerup","country":"DK","companyType":"pharma","website":"https://www.leo-pharma.com","stage":"private-large","investors":[],"funding":[]},"route":"/companies/leo-pharma/","neighbours":{"cancer":[{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/"}],"section":[{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"}]}}